An overview of the pharmacology and clinical efficacy of indapamide sustained release

Fundamental and Clinical Pharmacology

Volumn 19, Issue 6, 2005, Pages 637-645

  Sassard, J ^a   Bataillard, A ^a   McIntyre, H ^b  

^a UNIVERSITÉ LYON 1   (France)

^b St Leonards on Sea   (United Kingdom)

Author keywords

Hypertension; Indapamide SR; Pharmacokinetics; Pharmacology; Treatment efficacy

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE ACTIVITY; ARTERY COMPLIANCE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EVIDENCE BASED MEDICINE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYDROPHILICITY; HYPERTENSION; KALIURESIS; KIDNEY DISTAL TUBULE; MAXIMUM ALLOWABLE CONCENTRATION; META ANALYSIS; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULSE PRESSURE; REVIEW; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; TARGET ORGAN; UNSPECIFIED SIDE EFFECT; ALBUMINURIA; BLOOD; DELAYED RELEASE FORMULATION;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INDAPAMIDE; PRACTICE GUIDELINES;

EID: 33645229207     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2005.00377.x     Document Type: Review

References (42)

1. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet (2002) 360 1903-1913.
2. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 42 1206-1252.
3. Franklin S.S., Jacobs M.J., Wong N.D., et al. Predominance of isolated systolic hypertension among middle aged and elderly US hypertensives. Hypertension (2001) 37 869-874.
4. Collins R., Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease, in: Swales J. (Ed.), Textbook of hypertension. Blackwell Scientific Publications, Oxford, UK, 1994, pp. 1156-1164.
5. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288 2981-2997.
6. Chalmers J. All hats off to ALLHAT: a massive study with clear messages. J. Hypertens. (2003) 21 225-228.
7. Zanchetti A., Mancia G. The ALLHAT trial: a verdict or a challenge? J. Hypertens. (2003) 21 223.
8. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21 1011-1053.
9. Williams B., Poulter N.R., Brown M.J. et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). BMJ (2004) 328 634-640.
10. World Health Organization. International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J. Hypertens. (2003) 21 1983-1992.
11. Bataillard A., Schiavi P., Sassard J. Pharmacological properties of indapamide: rationale for use in hypertension. Clin. Pharmacokinet. (1999) 37(Suppl. 1) 7-12.
12. Campbell D.B., Taylor A.R., Hopkins Y.W., Williams J.R.B. Pharmacokinetics and metabolism of indapamide: a review. Curr. Med. Res. Opin. (1977) 5(Suppl. 1) 13-24.
13. Burk T.J., Nobles E.M., Wolf P.S. et al. Effect of indapamide on volume-dependent hypertension, renal hemodynamics, solute excretion and proximal nephron fractional reabsorption in the dog. Curr. Med. Res. Opin. (1983) 8(Suppl. 3) 25-34.
14. Moore R.A., Seki T., Oheim K. et al. Antihypertensive action of indapamide and review of pharmacology and toxicology. Curr. Med. Res. Opin. (1977) 5(Suppl. 1) 25-32.
15. Contard F., Sabri A., Glukohova M. et al. Arterial smooth muscle cell phenotype in stroke-prone spontaneously hypertensive rats. Hypertension (1993) 22 665-676.
16. Hayakawa H., Raij L. The link among nitric oxide synthase activity, endothelial function and aortic and ventricular hypertrophy in hypertension. Hypertension (1997) 29:235-241.
17. Pomiès J.P., Narcisse G., Gérard P. et al. Intérêts de l'indapamide dans la protection vasculaire chez la rat SHP-sp. Aspects histologiques. Arch. Mal. Coeur Vaiss. (1991) 84(HS):60.
18. Finch L., Hicks P.E., Oheim K. et al. The effects of indapamide on vascular reactivity in hypertension. Curr. Med. Res. Opin. (1977) 5(Suppl. 1) 44-54.
19. Mironneau J., Savineau J.P., Mironneau C. Compared effects of indapamide, hydrochlorothiazide and chlorthalidone on electrical and mechanical activities in vascular smooth muscle. Eur. J. Pharmacol. (1981) 75 109-113.
20. Uehara Y., Shirahase H., Naga T. et al. Radical scavengers of indapamide in prostacyclin synthesis in rat smooth muscle cell. Hypertension (1990) 15 216-224.
21. Damien G., Huet de Barochez B., Schiavi P. Galenic development and pharmacokinetic profile of indapamide sustained release 1.5 mg. Clin. Pharmacokinet. (1999) 37(Suppl. 1) 13-19.
22. Schiavi P., Jochemsen R., Guez D. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam. Clin. Pharmacol. (2000) 14 139-146.
23. Ambrosioni E., Safar M., Degaute J.P. et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release Indapamide: results of randomised double-blind controlled studies. J. Hypertens. (1998) 16 1677-1684.
24. Weidmann P. Metabolic profile of Indapamide sustained-release in patients with hypertension. Data from three randomised double-blind studies. Drug Safety (2001) 24(Suppl. 15) 1155-1165.
25. Guez D., Mallion J.M., Degaute J.P. et al. Traitement de l'hypertension artérielle par l'indapamide 1.5 mg, comprimé enrobé à libération prolongée: synthèse des résultats. Arch. Mal. Coeur Vaiss. (1996) 89 17-25.
26. Madkour H., Gadalah M., Riveline B., Plante G., Massry S. Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. Am. J. Cardiol. (1996) 77 23B-25B.
27. Leonetti G. Evaluation of long-term efficacy of indapamide SR in elderly hypertensive patients. Curr. Med. Res. Opin. (2005) 21 37-46.
28. Mallion J.M., Asmar R., Ambrosioni E., et al. Evaluation du rapport vallée:pic de l'indapamide 1.5 mg comprimé enrobé à libération prolongée par la mesure ambulatoire de la pression artérielle. Arch. Mal. Coeur Vaiss. (1996) 89 27-38.
29. Mallion J.M., Asmar R., Boutelant S., Guez D. Twenty-four-hour antihypertensive efficacy of indapamide 1.5 mg sustained-release: results of two randomized double-blind controlled studies. J. Cardiovasc. Pharmacol. (1998) 38 673-678.
30. Jaillon P., Asmar R. Blood pressure reduction over 32 hours in hypertensive patients after 2 months of combination therapy with indapamide SR. J. Hypertens. (2001) 19(Suppl. 2) S234.
31. Baguet J.-P., Robitail S., Boyer L., et al. A Meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am. J. Cardiovasc. Drugs (2005) 5 131-140.
32. Emeriau J.P., Knauf H., Pujadas J.O., et al. A comparison of indapamide SR 1.5 mg, with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J. Hypertens. (2001) 19 343-350.
33. London G., Calvo C., Schmieder R. Antihypertensive efficacy of indapamide SR vs candesartan and amlodipine in hypertensive patients: The X-CELLENT main study. J. Hypertens. (2004) 22(Suppl. 2) S384.
34. Gosse P., Sheridan D.J., Zannad F., et al. Regression of Left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 Versus Enalapril 20: the LIVE study. J. Hypertens. (2000) 18 1465-1475.
35. London G., Calvo C., Schmieder R., Asmar R. Indapamide SR antihypertensive efficacy vs candesartan and amlodipine in isolated systolic hypertensive patients: the X-CELLENT ISH subset. J. Hypertens. (2004) 22(Suppl. 2) S113-S114.
36. Somes G.W., Pahor M., Shorr R.I., Cushman W.C., Applegate W.B. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch. Intern. Med. (1999) 159 2004-2009.
37. London G., Calvo C., Schmieder R. Applanation tonometry: systolic blood pressure and pulse pressure (PP) under treatment with indapamide SR versus candesartan and amlodipine: the X-CELLENT tonometry study. J. Hypertens. (2004) 22(Suppl. 2) S275.
38. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. (1990) 322 1561-1566.
39. Mattock M.B., Morrish N.J., Viberti G., Keen H., Fitzgerald A.P., Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes (1992) 41 736-741.
40. Hallab M., Gallois Y., Chatellier G., Rohmer V., Fressinaud P., Marre M. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. BMJ (1993) 306 175-182.
41. Marre M., Garcia-Puig J., Kokot F., et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction hypertensive patients with type 2 diabetic: the NESTOR study. J. Hypertens. (2004) 22 1613-1622.
42. Preuss H.G., Burris J.F. Adverse metabolic effects of antihypertensive drugs: implications for treatment. Drug Safety (1996) 14 355-364.